anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ABSTRACT There are no effective disease modifying therapies for Multiple Sclerosis (MS). MS is characterized by immune system-mediated demyelination of the adult nervous system (NS). The present invention deals with an antibody directed against HERV-W. The claimed antibody targets a newly discovered detrimental mechanism which blocks the endogenous myelin repair capacity of the adult NS. This remyelination blockage is responsible for a progressive form of MS associated with the expression of HERV-W envelope protein (ENV). Therefore, targeting the HERV-W ENV with the claimed antibody would be beneficial for progressive MS patients. CA 2882781 2020-03-31
Myocardial infarction (MI) leads to a massive loss of cardiomyocytes, resulting in pathological cardiac remodeling and heart failure. Promoting cardiomyocyte regeneration is crucial for repairing the damaged heart. It is acknowledged that regenerative cardiomyocyte derives from the existing cardiomyocytes. In recent years, advancements in this field have updated our understanding of cardiomyocyte regeneration in many aspects, including intrinsic cell source and microenvironmental characteristics, extrinsic factors, molecular biology mechanisms, and intervention strategies. Here, we report a consensus by an expert committee on the definition, characteristics, evaluation, research methods, regulatory mechanisms, and intervention measures related to mammalian cardiomyocyte regeneration. The aim is to clarify important unresolved issues in this field and to promote myocardial regeneration research and its clinical translation.
PROBLEM TO BE SOLVED: To obtain a topical administration medicinal composition useful for treating and preventing periodontitis by adding minocycline and an aluminum compound to a polyhydric alcohol base agent. SOLUTION: This composition contains minocycline or its physiologically acceptable salt preferably in an amount of 0.1-5 wt.% based on the weight of the composition, an aluminum compound (e.g. aluminum lactate), preferably one or more substances selected from the group consisting of cellulose (e.g. crystal cellulose), cellulose derivatives and water-soluble polymeric compounds and further preferably a methacrylic acid-based copolymer preferably in an amount of 0.5-10 wt.% in a polyhydric alcohol base agent (preferably polyethylene glycol or glycerol). It is preferable that the composition is a viscous liquid- like or pasty composition. The composition may further be used as a medicine composition for skins and mucous membranes and for external uses.
Standard of care treatment plus the Reveal XT Implantable Cardiac Monitor. Treatment will follow the same schedule of the standard of care arm regarding exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. The addition will be device interrogation at every 6 month exam. Participation will last 36 months.
This study will enroll hypertensive patients who are in treatment or those who are referred from primary clinic based on inclusion or exclusion criteria. Basic clinical information, compliance with antihypertensive medications, concomitant use of other medications will be investigated and all patients will perform 24-hr ambulatory blood pressure measurement. Screening for renal artery stenosis and primary aldosteronism will be conducted. Office blood pressure will be taken every 3-6 months. Home blood pressure measurement and 24-hr ambulatory blood pressure measurement will be performed every year. The primary outcome is the newly developed MACE during the follow-up period. The secondary outcomes are newly developed target organ damage (LVH confirmed by echocardiography or EKG, carotid femoral PWV≥ 12m/s, microalbuminuria (Urine albumin-creatinine ratio ≥30 mg/g)) and decline of renal function (doubling of serum creatinine, dialysis). The follow-up period is 3 years.
Pain is the cardinal symptom of many debilitating diseases and results in heavy health and economic burdens worldwide. Asarum (Asarum sieboldii Miq.) is a commonly used analgesic in Chinese medicine. However, the analgesic components and mechanisms of asarum in acute and chronic pain mice model remain unknown. In this study, we first generated asarum water extract and confirmed strong analgesic properties in mice in both the acute thermal and mechanical pain models, as well as in the complete Freund's adjuvant (CFA) induced chronic inflammatory pain model. Second, we identified higenamine as a major component of asarum and found that higenamine significantly inhibited thermal and mechanical induced acute pain and CFA induced chronic inflammatory pain. Then, using Trpv4-/- mice, we found that TRPV4 is necessary for CFA induced thermal and mechanical allodynia, and demonstrated that higenamine analgesia in the CFA model is partly through TRPV4 channel inhibition. Finally, we found that GSK1016790A, a TRPV4 agonist, induced calcium response was significantly inhibited by higenamine in both cultured DRG neurons and TRPV4 transfected HEK293 cells. Consistent with calcium imaging results, higenamine pretreatment also dose-dependently inhibited GSK1016790A induced acute pain. Taken together, our behavior and calcium imaging results demonstrate that the asarum component higenamine inhibits acute and chronic inflammatory pain by modulation of TRPV4 channels.
A method and a platelet concentrate preservation device for platelet concentrate storage. A method includes at least partially saturating platelet concentrate xenon, and storing the platelet concentrate at less than 15C in a generally horizontal position. A device can be used to store blood, blood products, or combinations thereof that may or may not be under pressure. The device includes a chamber having a cavity. The chamber includes first and second chamber parts that form the cavity when releasably connected together. The cavity is designed to receive at least one bag that contains the blood, blood products, or combinations thereof. The device also includes a high-strength casing and includes a chamber cavity. The high-strength casing includes first and second casing parts that form the chamber cavity when releasably connected together. The chamber cavity is designed to receive the chamber.
The rising incidences of atherosclerosis have necessitated efforts to identify novel targets for therapeutic interventions. In the present study, we observed increased expression of the mechanosensitive calcium channel Piezo1 transcript in mouse and human atherosclerotic plaques, correlating with infiltration of PIEZO1-expressing macrophages. In vitro administration of Yoda1, a specific agonist for PIEZO1, led to increased foam cell apoptosis and enhanced phagocytosis by macrophages. Mechanistically, PIEZO1 activation resulted in intracellular F-actin rearrangement, elevated mitochondrial ROS levels and induction of mitochondrial fragmentation upon PIEZO1 activation, as well as increased expression of anti-inflammatory genes. In vivo, ApoE-/- mice treated with Yoda1 exhibited regression of atherosclerosis, enhanced stability of advanced lesions, reduced plaque size and necrotic core, increased collagen content, and reduced expression levels of inflammatory markers. Our findings propose PIEZO1 as a novel and potential therapeutic target in atherosclerosis.
The invention discloses well-being healthcare medicated wine and a preparation method thereof. The well-being healthcare medicated wine comprises white spirit, medlar, hawthorn and semen cassia. The preparation method includes steps of pretreating medlar, hawthorn and semen cassia, weighing raw materials, and placing medlar, hawthorn and semen cassia into the white spirit to prepare finished product. The well-being healthcare medicated wine has scent of wine and plants, is pure and mild, free of peculiar smell and odor, clear, transparent and free of sediments and suspensions. Various traditional Chinese medicine components capable of decreasing lipid, removing thrombus, nourishing the liver and improving eyesight are combined, and medical effect of single component can be successfully and doubly increased. Meanwhile, by the wine as carrier, medicine can be absorbed in human body, effect after absorption is better, yin is nourished and yang is suppressed, liver is tonified, eyesight is improved, and immunity is enhanced. Blood vessels can be softened and expanded, lipid is decreased, thrombus is removed, blood pressure is reduced, wine degrees of medicines are released, and taste of the well-being healthcare medicated wine is easy to accept.
Experimental group will consist of 12 patients with diagnosed Plantar Fasciitis, aged between 30-60 years. In addition to the conventional physiotherapy program, local release techniques will be applied to this group. Local Release Techniques will be applied as Gastro-solues trigger point myofascial release and Plantar fascia myofascial release. Participants will be treated for a total of 6 weeks, 2 days a week. Each treatment session will last 20-40 minutes.
The aberrant activation of NLRP3 inflammasome contributes to pathogenesis of multiple inflammation-driven human diseases. However, the medications targeting NLRP3 inflammasome are not approved for clinic use to date. Here, we show that ascorbyl palmitate (AP), a lipophilic derivative of ascorbic acid (AA) and a safe food additive, is a potent inhibitor of NLRP3 inflammasome. Compared with AA, AP inhibited the activation of NLRP3 inflammasome with increased potency and specificity. Mechanistically, AP directly scavenged mitochondrial reactive oxygen species (mitoROS) by its antioxidant activity and blocked NLRP3-NEK7 interaction and NLRP3 inflammasome assembly. Moreover, AP showed more significant preventive effects than AA in LPS-induced systemic inflammation, dextran sulfate sodium (DSS)-induced colitis and experimental autoimmune encephalomyelitis (EAE). Thus, our results suggest that AP is a potential therapeutic combating NLRP3-driven diseases.
Hypoglycemia is the most common adverse reaction of insulin, including LANTUS. The risk of hypoglycemia increases with intensive glycemic control. Patients must be educated to recognize and manage hypoglycemia. Severe hypoglycemia can lead to unconsciousness or convulsions and may result in temporary or permanent impairment of brain function or death. Severe hypoglycemia requiring the assistance of another person or parenteral glucose infusion or glucagon administration has been observed in clinical trials with insulin, including trials with LANTUS. 

The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulations. Other factors such as changes in food intake (e.g., amount of food or timing of meals), exercise, and concomitant medications may also alter the risk of hypoglycemia [See Drug Interactions (7)]. 

The prolonged effect of subcutaneous LANTUS may delay recovery from hypoglycemia. Patients being switched from twice daily NPH insulin to once-daily LANTUS should have their initial LANTUS dose reduced by 20% from the previous total daily NPH dose to reduce the risk of hypoglycemia [see Dosage and Administration (2.3)].

As with all insulins, use caution in patients with hypoglycemia unawareness and in patients who may be predisposed to hypoglycemia (e.g., the pediatric population and patients who fast or have erratic food intake). The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery.

Early warning symptoms of hypoglycemia may be different or less pronounced under certain conditions, such as longstanding diabetes, diabetic neuropathy, use of medications such as beta-blockers, or intensified glycemic control. These situations may result in severe hypoglycemia (and, possibly, loss of consciousness) prior to the patient's awareness of hypoglycemia.
PROBLEM TO BE SOLVED: To obtain a solid preparation for oral administration, containing fine powder nitrendipine readily absorbable without an absorption promoter, comprising fine powder nitrendipine having a specific particle diameter as an active ingredient. SOLUTION: This preparation comprises fine powder nitrendipine having an average particle diameter equal to or smaller than several μm, preferably <=6μm, more preferably >=43μm. The crystalline fine powder nitrendipine is obtained only by pulverizing crystalline raw powder nitrendipine. The nitrendipine is also obtained by transferring amorphous nitrendipine by external energy such as heat or pressure or in the presence of water by a well-known method. This fine powder nitrendipine thus obtained is made into a granular state by a fluidized bed or a high-speed stirring granulation method and tableted to give a solid preparation for oral administration. Preferably, 5-10 pts.wt. (the total amount of 80 pts.wt.) of the fine powder nitrendipine is contained in the solid preparation.  Even in the case of the oral administration of the solid preparation, improvement in availability in vivo is expected.
<P>PROBLEM TO BE SOLVED: To provide a pretreating material composition which enables the simple understanding of a suitable pretreating time at a clinical dental treatment site on the pretreatment of the un-ground enamel of tooth before an adhesive treatment, wherein insufficient decalcification or excessive decalcification is liable to be caused only by a constant pretreating time, because the easiness of the decalcification and thereby a suitable pretreating time are largely different due to the uptake of fluorine or the adhesion of dental plaques.  <P>SOLUTION: This pretreating material used for dentistry and comprising a 30 to 50 mass % aqueous phosphoric acid solution is characterized by containing a coloring substance represented by the formula [Q<SP>n+</SP>is an n-valent cation such as K<SP>+</SP>or N<SP>+</SP>; (n) is an integer of 1 to 3]. The color of the pretreating material containing the coloring substance is first yellowish green to green, but is changed with the advance of the decalcification. When the decalcification advances to a needed level, the color of the pretreating material is changed into a light blue color at the approximately same timing. Thereby, when the pretreating material is immediately washed with water at the time of the change into the color, excessive decalcification can be prevented, and the risk of the dental caries of the pretreated portion can hence be lowered.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Patients will undergo myocardial perfusion scintigraphy and CD34+ cells will be injected intracoronary in the artery supplying segments of reduced viability. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure.
AmBisome was studied in patients with visceral leishmaniasis who were infected in the Mediterranean basin with documented or presumed Leishmania infantum. Clinical studies have not provided conclusive data regarding efficacy against L. donovani or L. chagasi. 

AmBisome achieved high rates of acute parasite clearance in immunocompetent patients when total doses of 12-30 mg/kg were administered. Most of these immunocompetent patients remained relapse-free during follow-up periods of 6 months or longer. While acute parasite clearance was achieved in most of the immunocompromised patients who received total doses of 30-40 mg/kg, the majority of these patients were observed to relapse in the 6 months following the completion of therapy. Of the 21 immunocompromised patients studied, 17 were coinfected with HIV; approximately half of the HIV-infected patients had AIDS. The following table presents a comparison of efficacy rates among immunocompetent and immunocompromised patients infected in the Mediterranean basin who had no prior treatment or remote prior treatment for visceral leishmaniasis. Efficacy is expressed as both acute parasite clearance at the end of therapy (EOT) and as overall success (clearance with no relapse) during the follow-up period (F/U) of greater than 6 months for immunocompetent and immunocompromised patients:

  
When followed for 6 months or more after treatment, the overall success rate among immunocompetent patients was 96.5% and the overall success rate among immunocompromised patients was 11.8% due to relapse in the majority of patients. While case reports have suggested there may be a role for long-term therapy to prevent relapses in HIV coinfected patients (Lopez-Dupla, et al. J Antimicrob Chemother 1993; 32: 657-659), there are no data to date documenting the efficacy or safety of repeat courses of AmBisome or of maintenance therapy with this drug among immunocompromised patients.
Chronic pelvic pain (CPP) is the primary symptom of endometriosis patients, but adequate treatments are lacking. Modulation of ion channels expressed by sensory nerves innervating the viscera has shown promise for the treatment of irritable bowel syndrome and overactive bladder. However, similar approaches for endometriosis-associated CPP remain underdeveloped. Here, we examined the role of the voltage-gated sodium (NaV) channel NaV1.7 in (i) the sensitivity of vagina-innervating sensory afferents and investigated whether (ii) NaV1.7 inhibition reduces nociceptive signals from the vagina and (iii) ameliorates endometriosis-associated CPP. The mechanical responsiveness of vagina-innervating sensory afferents was assessed with ex vivo single-unit recording preparations. Pain evoked by vaginal distension (VD) was quantified by the visceromotor response (VMR) in vivo. In control mice, pharmacological activation of NaV1.7 with OD1 sensitised vagina-innervating pelvic afferents to mechanical stimuli. Using a syngeneic mouse model of endometriosis, we established that endometriosis sensitised vagina-innervating pelvic afferents to mechanical stimuli. The highly selective NaV1.7 inhibitor Tsp1a revealed that this afferent hypersensitivity occurred in a NaV1.7-dependent manner. Moreover, in vivo intra-vaginal treatment with Tsp1a reduced the exaggerated VMRs to VD which is characteristic of mice with endometriosis. Conversely, Tsp1a did not alter ex vivo afferent mechanosensitivity nor in vivo VMRs to VD in Sham control mice. Collectively, these findings suggest that NaV1.7 plays a crucial role in endometriosis-induced vaginal hyperalgesia. Importantly, NaV1.7 inhibition selectively alleviated endometriosis-associated CPP without the loss of normal sensation, suggesting that selective targeting of NaV1.7 could improve the quality of life of women with endometriosis.
The invention relates to a Chinese medicinal composition for treating adolescent polycystic ovary syndrome. The invention is characterized in that the Chinese medicinal composition is prepared by mixing 40-50 parts of a monarch drug, 35-47 parts of a minister drug, and 160-210 parts of an assistant drug. Specifically, the monarch drug consists of Angelica sinensis and Radix Paeoniae Alba, and the minister drug is composed of radix curcumae, roses and stir-fried Radix Scutellariae. The assistant drug is formed by mixing, by weight, 10-30 parts of medlar, 26-32 parts of mulberry fruits, 12-18 parts of spina gleditsiae, 12-18 parts of seaweed, 12-18 parts of acorus gramineus, 12-18 parts of prunella vulgaris, 12-18 parts of radix cyathulae, 28-35 parts of Salvia miltiorrhiza and 28-35 parts of raw hawthorn. In the monarch drug, a weight ratio of the Angelica sinensis to the Radix Paeoniae Alba is 1:1. And the minister drug is composed of, by weight, 6-11 parts of radix curcumae, 6-11 parts of roses and 10-15 parts of stir-fried Radix Scutellariae.
BACKGROUND: Retinal ischemia-refusion (I/R) is a leading cause of irreversible blindness worldwide. This study aims to explore the regulatory role of SOX9 in retinal I/R injury, and attempts to elucidate its potential regulatory mechanism.
METHODS: Retinal I/R injury model was established in vivo, and the histological changes was examined by hematoxylin and eosin (H&E) staining and immunofluorescent assay was performed to examine SOX9 expression. Oxygenation-glucose deprivation/reoxygenation (OGD/R)-induced retinal ischemia/reperfusion (I/R) injury in 661 W cells was constructed as an in vitro cellular model of glaucoma. The production of cytokines, lactate dehydrogenase (LDH) and the antioxidant enzymes were assessed by their commercial kits. Cellular reactive oxygen species (ROS) and lipid ROS was detected using DCFH-DA and C11-BODIPY 581/591 staining, respectively. Lipid peroxidation and Fe2+ level were detected to assess the ferroptosis level. Protein expression was examined by western blot. LM22B-10, the agonist of ERK signaling, was used to pretreat 661 W cells for mechanism investigation.
RESULTS: SOX9 was aberrantly upregulated following retinal I/R injury both in vivo and in vitro. SOX9 knockdown exerted a protective role against OGD/R-triggered oxidative stress, inflammatory response and ferroptosis in 661 W cells. Further, ERK/p38 signaling was activated in 661 W cells following OGD/R induction, which was repressed by SOX9 knockdown, and the ERK signaling agonist partially counteracted the protective role of SOX9 knockdown against oxidative stress, inflammatory response and ferroptosis in OGD/R-induced 661 W cells.
CONCLUSION: Collectively, inhibiting SOX9 to block oxidative stress, inflammation and ferroptosis by inactivating ERK/p38 signaling might be effective to prevent retinal I/R injury, thereby alleviating glaucoma.
The goal of ASAP was to facilitate maximal walking ability of stroke patients by standardized application of modern technologies. ASAP features standardized functional assessment, standardized intensive early ambulation with modern technologies such as Knee-Ankle-Foot Orthoses, Lower Limb Robotic-Assisted Gait Training and Video-Guide Training. In order to monitor the progress of each patient proactively, Stroke Registry and Reference Modified Rivermead Mobility Index (MRMI) Gain were developed. Stroke Registry was a longitudinal stroke rehabilitation database to monitor patients' functional outcome and therapists' intervention compliance. Reference MRMI Gain was a clinical prediction model based on big data concept to support goal-orientated approach of physiotherapists in stroke rehabilitation. Stroke treatment library, a standardized exercise prescription in video format was also developed to facilitate standardized prescription of interventions to patients with different level of ability.
PURPOSE: To obtain a hair dyeing composition not showing selectivity to damage caused by permanent wave, comprising a component containing a monohydroxyindole and a 5,6-substituted hydroxyindole and a component containing periodic acid, separately respectively. CONSTITUTION: A medium suitable for dyeing is formulated with 0.01-5wt.% of a monohydroxyindole of formula I (R1 is H or a 1-4C alkyl; R2 and R3 are each H, NH2 , OH, COOH, etc.) and 0.01-5wt.% of a 5,6-substituted hydroxyindole of formula II (R4 is H, methyl, carboxyl, etc.; R5 is H, methyl, etc.; R6 is H or acetyl) to give a composition A. Separately a medium suitable for dyeing is mixed with 0.04-0.07 mol based on 100g of a composition B of periodic acid or its salt to give the composition B. The composition A is applied to a keratin hair, specific human hair, which is rinsed. The composition B is applied to the hair to carry out dyeing.